Diagnostic Performance of Commercial Antithrombin Activity Assays: Do We Get What We Expect?

Abstract

Background

Hereditary antithrombin (AT) deficiency is a rare autosomal dominant disorder that predisposes to the development of recurrent venous thromboembolism (VTE). Diagnosis is based on the measurement of reduced AT activity in plasma. However, not all commercial AT activity assays are equally suited for diagnosis since they differ in sensitivity toward different AT mutations.

Objectives and Methods

The aim of this study was to compare the ability of commonly used AT activity assays to diagnose inherited antithrombin deficiency, with a focus on type II AT deficiencies. We used samples from genetically confirmed AT deficient subjects (n = 76) and from patients with request for AT activity measurement for diagnostic purposes (n = 152). AT activity was measured with five commercial assays on three analyzers.

Results and Conclusion

All reagent/analyzer combinations showed specificities varying from 87 to 100%, except for 1 assay (56.5% specificity). Diagnostic sensitivity varied widely between assays, from 36.8% to 100%. All reagent–analyzer combinations correctly identified variants causing type I AT deficiencies but only one variant responsible for type II heparin binding site (HBS) deficiency: p.Arg79Cys. For one of the assays, we observed a large difference in sensitivity (82.9 versus 55.3%) toward antithrombin type II HBS variants depending on the coagulation analyzer on which it is performed, suggesting that incubation time of sample and substrate could be a crucial driver of the sensitivity toward variants causing type II antithrombin deficiency. Our results suggest that inherited antithrombin deficiency is probably underestimated and improved diagnostic strategies are mandatory.

Keywords

antithrombin - antithrombin deficiency - diagnostic performance - heparin binding site - thrombophilia

Publication History

Received: 14 February 2025

Accepted: 04 June 2025

Accepted Manuscript online:
05 June 2025

Article published online:
24 June 2025

• References

• 1 Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14 (06) 1229-1239
• 2 Corral J, de la Morena-Barrio ME, Vicente V. The genetics of antithrombin. Thromb Res 2018; 169: 23-29
• 3 Tait RC, Walker ID, Perry DJ. et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87 (01) 106-112
• 4 Wells PS, Blajchman MA, Henderson P. et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Hematol 1994; 45 (04) 321-324
• 5 Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126 (11) 1326-1336
• 6 Bravo-Pérez C, de la Morena-Barrio ME, Palomo A. et al. Genotype-phenotype gradient of SERPINC1 variants in a single family reveals a severe compound antithrombin deficiency in a dead embryo. Br J Haematol 2020; 191 (01) e32-e35
• 7 Ishiguro K, Kojima T, Kadomatsu K. et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106 (07) 873-878
• 8 Croles FN, Borjas-Howard J, Nasserinejad K, Leebeek FWG, Meijer K. Risk of venous thrombosis in antithrombin deficiency: a systematic review and Bayesian meta-analysis. Semin Thromb Hemost 2018; 44 (04) 315-326
• 9 Van Cott EM, Orlando C, Moore GW, Cooper PC, Meijer P, Marlar R. Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; communication from the SSC of the ISTH. J Thromb Haemost 2020; 18 (01) 17-22
• 10 Cooper PC, Coath F, Daly ME, Makris M. The phenotypic and genetic assessment of antithrombin deficiency. Int J Lab Hematol 2011; 33 (03) 227-237
• 11 Muszbek L, Bereczky Z, Kovács B, Komáromi I. Antithrombin deficiency and its laboratory diagnosis. Clin Chem Lab Med 2010; 48 (Suppl. 01) S67-S78
• 12 Orlando C, Heylen O, Lissens W, Jochmans K. Antithrombin heparin binding site deficiency: a challenging diagnosis of a not so benign thrombophilia. Thromb Res 2015; 135 (06) 1179-1185
• 13 Kovács B, Bereczky Z, Oláh Z. et al. The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site antithrombin deficiency. Am J Clin Pathol 2013; 140 (05) 675-679
• 14 European Parliament and Council Regulation (EU) 2017/746 of 5 April 2017 on in vitro diagnostic medical devices. Off J Eur Union 2017; 117: 176-332
• 15 Caspers M, Pavlova A, Driesen J. et al. Deficiencies of antithrombin, protein C and protein S—practical experience in genetic analysis of a large patient cohort. Thromb Haemost 2012; 108 (02) 247-257
• 16 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 17 Harper PL, Daly M, Price J, Edgar PF, Carrell RW. Screening for heparin binding variants of antithrombin. J Clin Pathol 1991; 44 (06) 477-479
• 18 Rojnik T, Sedlar N, Turk N, Kastrin A, Debeljak M, Božič Mijovski M. Comparison of antithrombin activity assays in detection of patients with heparin binding site antithrombin deficiency: systematic review and meta-analysis. Sci Rep 2023; 13 (01) 16734
• 19 Gindele R, Selmeczi A, Oláh Z. et al. Clinical and laboratory characteristics of antithrombin deficiencies: a large cohort study from a single diagnostic center. Thromb Res 2017; 160: 119-128
• 20 Javela K, Engelbarth S, Hiltunen L, Mustonen P, Puurunen M. Great discrepancy in antithrombin activity measured using five commercially available functional assays. Thromb Res 2013; 132 (01) 132-137
• 21 Corral J, Hernandez-Espinosa D, Soria JM. et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109 (10) 4258-4263
• 22 Le Cam Duchez V, Deshayes A, Delarue E. PB0991 Clinical performance evaluation of a new Stago system for antithrombin levels determination: sthemO AT on sthemO 301. Res Pract Thromb Haemost 2023 ;7(Suppl 2)
• 23 Rühl H, Reda S, Müller J, Oldenburg J, Pötzsch B. Activated factor X-based versus thrombin-based antithrombin testing in thrombophilia workup in the DOAC era. Thromb Haemost 2018; 118 (02) 381-387
• 24 Navarro-Fernández J, de la Morena-Barrio ME, Padilla J. et al. Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. Thromb Haemost 2016; 116 (01) 146-154
• 25 Borg JY, Brennan SO, Carrell RW, George P, Perry DJ, Shaw J. Antithrombin Rouen-IV 24 Arg—-Cys. The amino-terminal contribution to heparin binding. FEBS Lett 1990; 266 (1-2): 163-166
• 26 Maruyama K, Morishita E, Karato M. et al. Antithrombin deficiency in three Japanese families: one novel and two reported point mutations in the antithrombin gene. Thromb Res 2013; 132 (02) e118-e123
• 27 Schedin-Weiss S, Desai UR, Bock SC, Olson ST, Björk I. Roles of N-terminal region residues Lys11, Arg13, and Arg24 of antithrombin in heparin recognition and in promotion and stabilization of the heparin-induced conformational change. Biochemistry 2004; 43 (03) 675-683
• 28 Lane DA, Olds RJ, Conard J. et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90 (06) 2422-2433
• 29 Luxembourg B, Delev D, Geisen C. et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105 (04) 635-646
• 30 Kumar R, Chan AK, Dawson JE, Forman-Kay JD, Kahr WH, Williams S. Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study. Br J Haematol 2014; 166 (01) 130-139
• 31 Bravo-Pérez C, Toderici M, Chambers JE. et al. Full-length antithrombin frameshift variant with aberrant C-terminus causes endoplasmic reticulum retention with a dominant-negative effect. JCI Insight 2022; 7 (19) e161430
• 32 Luxembourg B, Pavlova A, Geisen C. et al. Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency. Thromb Haemost 2014; 111 (02) 249-257
• 33 Alhenc-Gelas M, Plu-Bureau G, Hugon-Rodin J, Picard V, Horellou MH. GFHT study group on Genetic Thrombophilia. Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency. Thromb Haemost 2017; 117 (06) 1040-1051
• 34 Puurunen M, Salo P, Engelbarth S, Javela K, Perola M. Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture. J Thromb Haemost 2013; 11 (10) 1844-1849